Surge Therapeutics Raises $26M in Series A Funding

cancer

Surge Therapeutics, a Cambridge, MA-based biotechnology corporate, raised $26M in Collection A investment.

The spherical used to be led via Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, Alumni Ventures, and the Most cancers Analysis Institute.

The corporate intends to make use of the finances to boost up building of its intraoperative immunotherapy manner, increase the group, and begin scientific trials for its injectable biodegradable hydrogel.

Led via CEO and Founder Dr. Michael Goldberg, Surge Therapeutics is an organization growing an injectable biodegradable hydrogel that allows prolonged, localized free up of most cancers immunotherapy on the web page of surgical tumor resection to make stronger affected person survival results.

Constructed upon analysis performed in founder and CEO Dr. Michael Goldberg’s laboratory at Harvard Clinical College, the SURGE Therapeutics™ injectable biodegradable hydrogel allows prolonged, localized free up of most cancers immunotherapy on the web page of surgical tumor resection. In a couple of competitive murine fashions of metastasizing most cancers, intraoperative immunotherapy massively progressed survival get advantages relative to conventional routes of management, whether or not systemic or native. Dr. Goldberg finished his PhD and post-doctoral coaching at MIT underneath the mentorship of Robert Langer and Phillip Sharp, respectively.

The corporate has a group of operators and advisors that come with leaders in localized therapeutics, drug supply, translational immunotherapy, surgical oncology, drug building, and immune-engineering: Charles (“Chuck”) Carignan, MD (former Leader Clinical Officer of Boston Medical), Robert Langer, ScD (founding father of Moderna), Elizabeth Jaffee, MD (Previous-President of the American Affiliation for Most cancers Analysis), Timothy Eberlein, MD (Previous-President of the Society of Surgical Oncology), Francis Cuss, MD (former Leader Medical Officer of Bristol Myers Squibb), and Darrell Irvine, PhD (HHMI Investigator).

FinSMEs

17/10/2022

Leave a Comment